Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avastin Widespread Availability For Eye Use May Depend On FDA Clearance

Executive Summary

FDA has taken center stage in the skirmish over Avastin's off-label use in patients with age-related macular degeneration

You may also be interested in...

Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions

Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups

Off-Label Dissemination May Be Clarified – Indirectly – By FDAAA Regs

Issues surrounding off-label dissemination may be clarified through regulations required by the FDA Amendments Act of 2007

CMS May Take Lead In Federal Compounding Oversight After Court Ruling

The Centers for Medicare & Medicaid Services may serve as a stronger regulatory presence for pharmacy compounders in light of a recent federal court decision rejecting FDA's enforcement authority over the practice

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts